Home » Note to Readers

Note to Readers

Dec 20, 2012
Premium

This will be the last issue of Gene Silencing News for 2012. The next issue will go out to subscribers on January 3, 2013. Happy holidays!

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Related Articles

Jun 19, 2014

Alnylam Touts HBV IP amid Competition from Arrowhead, Tekmira

Premium
Apr 03, 2014

Dicerna Provides Pipeline Update, Weighs Potential of Delivery Tech for mRNA Drugs

Premium
Aug 07, 2014

Regulus Sets Bar High for HCV Program, Sees Alport Drug in Phase II by 2015

Premium
Jun 12, 2014

Regulus Weighs Spinoff of microRNA Biomarker Unit

Premium
Apr 24, 2014

Amid Biotech Downturn, Stocks of RNAi/microRNA Shops Hit Hard

Premium
May 15, 2014

EPA Releases Advisory Panel Recommendations on Agricultural RNAi Risk Assessment

Premium

The Scan

This Week in Science

In Science this week: gene linked to expansion of the human neocortex, and more.

Bit of an Increase

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient Wheat

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

'High School Never Ends'

Joel Achenbach explores at National Geographic why people find science difficult to believe.

What's Popular?

In miRNA/RNAi

  1. New RNAi Technique Shows Complete Crop Protection from Key Pest

    Premium

  2. New Study Shows Most Exosomes Don't Carry Many microRNAs

    Premium

  3. GeneSegues Secures $1M NCI Contract to Develop Cancer Therapeutic

    Premium

  4. Q&A: Whitehead's Richard Possemato on RNAi Screening in Breast Cancer

    Premium

  5. Genotyping/Sequencing Combination Identifies Glioma Risk Variant with Possible miRNA Role

    Premium

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.